Probiotics in Pediatrics
Direct Recommendation
For preterm infants (<37 weeks gestational age), use specific combinations of Lactobacillus and Bifidobacterium strains to prevent necrotizing enterocolitis (NEC) and reduce mortality; however, do NOT use probiotics for acute infectious gastroenteritis in otherwise healthy children in North America. 1
Preterm Infants: Strong Evidence for Use
Recommended Strains and Combinations
The 2020 AGA guidelines provide a conditional recommendation (moderate/high quality evidence) for specific probiotic regimens in preterm infants (<37 weeks gestational age) with low birth weight 1:
Combination therapy (preferred):
- L. rhamnosus ATCC 53103 + B. longum subsp infantis
- L. acidophilus + B. longum subsp infantis
- L. acidophilus + B. bifidum
- L. rhamnosus ATCC 53103 + B. longum Reuter ATCC BAA-999
- Multi-strain: L. acidophilus, B. bifidum, B. animalis subsp lactis, B. longum subsp longum
Single-strain alternatives:
- B. animalis subsp lactis (including DSM 15954)
- L. reuteri (DSM 17938 or ATCC 55730)
- L. rhamnosus (ATCC 53103)
Clinical Benefits in Preterm Infants
The evidence demonstrates substantial mortality and morbidity reduction. Network meta-analysis of 63 studies showed combinations of Lactobacillus and Bifidobacterium species reduced all-cause mortality (OR 0.56,95% CI 0.39-0.80) 1.
Recent 2026 data from Dutch NICUs using a three-strain product (B. infantis Bb-02, B. lactis BB-12, S. thermophilus TH-4) in extremely preterm infants (<28 weeks) demonstrated:
- 51% reduction in NEC incidence (adjusted OR 0.49,95% CI 0.25-0.99)
- 2-day shorter time to full enteral feeds
- Increased growth velocity by 1.8 g/kg/day
- Only 1 case (0.4%) of probiotic-associated sepsis in 269 infants 2
This is particularly important as it addresses the longstanding concern about safety in the most vulnerable extremely preterm population.
Dosing and Duration
While the guidelines specify strains, specific dosing regimens vary by product. The ESPGHAN position paper recommends L. rhamnosus GG ATCC53103 or the combination of B. infantis Bb-02, B. lactis Bb-12, and S. thermophilus TH-4 with a conditional recommendation 3. Supplementation typically continues until discharge or 36 weeks postmenstrual age, though optimal duration requires further study 4.
Acute Infectious Gastroenteritis in Children: Do NOT Use
The AGA explicitly recommends AGAINST probiotics for acute infectious gastroenteritis in children in North America 1. This is a critical divergence from global evidence.
Why This Matters
While meta-analyses showed some strains (particularly S. boulardii and L. rhamnosus ATCC 53103) reduced diarrhea duration by 21-29 hours in studies conducted globally, two large North American multicenter RCTs fundamentally changed this recommendation:
- US Pediatric Emergency Care Applied Research Network (n=943): L. rhamnosus ATCC 53103 showed NO benefit
- Canadian Pediatric Emergency Research Canada (n=827): L. rhamnosus R0011 + L. helveticus R0052 showed NO benefit
The guidelines attribute this to differences in host genetics, diet, sanitation, and endemic enteropathogens between North America and other regions 1. This geographic specificity is essential—do not extrapolate international gastroenteritis data to North American practice.
Other Pediatric Indications
The 2023 ESPGHAN guidelines 5 provide recommendations for additional conditions, though with varying strength of evidence:
Conditions with Some Evidence:
- Antibiotic-associated diarrhea prevention: Specific strains may reduce incidence
- Helicobacter pylori infection management: As adjunct to standard therapy
- Functional abdominal pain disorders: Selected strains for specific presentations
- Infant colic: Limited evidence for specific strains
Important caveat: These recommendations require at least 2 RCTs on similar well-defined strains and use modified Delphi consensus. The evidence quality varies significantly by condition and strain.
Safety Considerations
Critical Safety Requirements for Preterm Infants
Before implementing probiotics in preterm populations, ensure 3:
- Product quality assurance: Verified strain identity and viability
- Antibiotic resistance screening: Strains must lack transferable resistance genes
- Microbiological surveillance: Local labs must be able to detect probiotic-associated sepsis
- Monitoring protocols: Track for signs of sepsis, feeding intolerance
Risk-Benefit in Extremely Preterm Infants
The 2026 Dutch study provides reassuring safety data with only 0.4% probiotic-associated sepsis in extremely preterm infants 2, supporting continued use when proper safety protocols are followed. However, this remains a vulnerable population requiring vigilant monitoring.
Common Pitfalls to Avoid
- Strain specificity matters: Do not substitute one probiotic strain for another—efficacy is strain-specific
- Geographic context: Do not use probiotics for pediatric gastroenteritis in North America despite positive international data
- Product quality: Ensure commercial products contain verified strains at appropriate concentrations
- Immunocompromised patients: Exercise extreme caution; probiotics may pose sepsis risk
- Unsupported indications: Avoid probiotics with "no documented health benefits" 5
Algorithm for Clinical Decision-Making
Step 1: Identify patient population
- Preterm infant (<37 weeks GA) → Proceed to Step 2
- Term infant/child with acute gastroenteritis in North America → Do NOT use probiotics
- Other pediatric GI condition → Consult ESPGHAN guidelines for strain-specific recommendations 5
Step 2: For preterm infants, verify safety requirements
- Product quality confirmed?
- No transferable antibiotic resistance?
- Monitoring capability for probiotic sepsis?
- If YES to all → Proceed to Step 3
- If NO to any → Address gaps before implementation
Step 3: Select appropriate strain/combination
- Prefer Lactobacillus + Bifidobacterium combinations
- Use specific strains listed in AGA guidelines 1
- Continue until discharge or 36 weeks postmenstrual age